Broad Health Condition Cancer
Cancer
Cancer
Cancer
Cancer
Cancer
Cancer
Blood

Specific Health ConditionHodgkin's
Leukaemia - Acute leukaemia
Leukaemia - Chronic leukaemia
Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma
Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma
Myeloma
Other cancer types
Other blood disorders

Trial FocusTreatment

Recruitment statusRecruiting

Recruitment Details
Recruitment State
VIC

Hospital
Cabrini Hospital - Malvern - Malvern


Postcode
3144 - Malvern

Anticipated date of first participant enrolment9/03/2020

Anticipated date of last participant enrolment9/03/2020

Phase of TrialNot Applicable

Has the study received ethics approval?Approved

Trial summary

The purpose of this study is to test a new screening tool to see if this tool helps the hospital meet patient’s supportive care needs. Supportive care includes physical, financial, emotional, family and practical support.

Who is it for?
You may be eligible for this study if you are aged 16 or over, you have a diagnosis of blood cancer and are receiving treatment. You may also be eligible for a part of the study if you have received treatment for a blood cancer in the past.

Study details
Participants in this study will be divided into two groups, depending on whether they are currently having treatment (called the prospective group), or received treatment in the past (the retrospective group). Both groups will complete screening tools, which involve a questionnaire. The retrospective group will complete a paper questionnaire and return by mail. The prospective group will complete the questionnaire at each appointment in a 12-month period. In addition to the questionnaire(s), all participants will also complete a satisfaction survey.

It is hoped this research will demonstrate the usefulness of this screening process, and enable the needs of patients to be responded to more effectively.

Key inclusion criteria

Prospective arm:
1. Participants with a diagnosis of haematological malignancy (including, but not limited to, myeloma, lymphoma, leukaemia, myelodysplastic and myeloproliferative syndromes), attending the study centre
2. In receipt of treatment for their haematological malignancy during the twelve-month study period (including, but not limited to, parenteral chemotherapy and immunotherapy, oral chemotherapy/disease directed therapy or regular blood product transfusions)

Retrospective arm:
1. Participants with a diagnosis of haematological malignancy (including, but not limited to, myeloma, lymphoma, leukaemia, myelodysplastic and myeloproliferative syndromes)
2. Attended the study centre between 28/05/19 - 27/05/2020 for treatment of their haematological malignancy

Minimum age16 Years

GenderBoth males and females

Can Healthy volunteers participate?No

Key exclusion criteria

For both prospective and retrospective arms, patients who are unable to speak or write the English language are not eligible for participation in this study.